Larvol Delta - Generation-S2-A-Study-of-CNP520-Versus-Placebo-in-Participants-at-Risk-for-the-Onset-of-Clinical-Symptoms-of-Alzheimer39s-Disease

umibecestat (CNP520) - Novartis, Amgen, Banner Alzheimer’s Institute

http://clinicaltrials.gov/ct2/show/NCT03131453

Aug 18, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next